The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of homologous recombination repair (HRR) status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays.
 
Pablo Cresta Morgado
No Relationships to Disclose
 
Sara Arce-Gallego
No Relationships to Disclose
 
Luisa Delgado-Serrano
No Relationships to Disclose
 
Sara Simonetti
No Relationships to Disclose
 
Macarena González
Consulting or Advisory Role - Bayer; Ipsen
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Lilly; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
 
David Humberto Marmolejo Castañeda
No Relationships to Disclose
 
Rafael Morales-Barrera
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck/Pfizer; MSD; Sanofi
Speakers' Bureau - Astellas Pharma; Merck/Pfizer; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; MSD; Pfizer; Roche/Genentech; Sanofi
 
Jacques Planas
No Relationships to Disclose
 
Paula Romero-Lozano
No Relationships to Disclose
 
Xavier Maldonado
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen
Travel, Accommodations, Expenses - BAYER; Ipsen; Recordati
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Mariona Figols
Consulting or Advisory Role - Astellas Pharma; Merck
Travel, Accommodations, Expenses - Merck
 
Sara Cros
No Relationships to Disclose
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Stock and Other Ownership Interests - Trialing Health
Consulting or Advisory Role - Boehringer Ingelheim; Foundation Medicine; Roche
Speakers' Bureau - Amgen; AstraZeneca; GlaxoSmithKline; Ipsen; Janssen Oncology; Libbs; Lilly; MSD Oncology; Roche; Sanofi; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck; Novartis (Inst)
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; Novartis; Targos GmbH
Consulting or Advisory Role - Bayer; MSD Oncology; Targos GmbH
Travel, Accommodations, Expenses - Novartis
 
Ana Vivancos
Stock and Other Ownership Interests - Reveal Genomics
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Guardant Health; Incyte; Merck; Roche
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst)
 
Alba Llop-Guevara
No Relationships to Disclose
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
Other Relationship - Catalan Program of Ambulatory Medication Comission (CAHMDA)
 
Violeta Serra
Honoraria - AstraZeneca Spain
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca; GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Patent based on a method to identify PARP inhibitor sensitive tumors
 
Joaquin Mateo
Consulting or Advisory Role - Amunix; AstraZeneca; Daiichi Sankyo Europe GmbH; Illumina; MSD; Nuage Therapeutics; Pfizer
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Pfizer (Inst)
Other Relationship - Nuage Therapeutics